Before you sell to, join or invest in OncoResponse, Inc
MentionFox check on OncoResponse, Inc: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/oncoresponse-inc-form-d-25000001
Check OncoResponse, Inc before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about OncoResponse, Inc?
Based on the record MentionFox holds for this company. No flag is not a clearance.
OncoResponse, Inc filed a Form D with the Securities and Exchange Commission on 2025-05-06.
OncoResponse, Inc filed a Form D notice of an exempt securities offering with the SEC on May 6, 2025. The filing reports $6M sold. Its industry group is Biotechnology. It names Clifford Stocks (Director, Executive Officer), Alice Bexon (Executive Officer), Kamal Puri (Executive Officer) (SEC Form D, May 6, 2025).
Is this your company?
Sell to companies like OncoResponse, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns OncoResponse, Inc.
Free to see. No signup.
More on the people and the money behind OncoResponse, Inc, from the filings we hold.
Biotechnology raises by companies based in Texas, filed in May 2025, largest first.
Get an email when OncoResponse, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when OncoResponse, Inc raises, hires or launches. No email unless you switch it on.
Watch OncoResponse, Inc →Get the full cited report on OncoResponse, Inc
What the filing shows about OncoResponse, Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on OncoResponse, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives OncoResponse, Inc's address as 609 Main Street, Suite 4200, Houston, TX 77002.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
OncoResponse, Inc is a registered filer with the SEC (CIK 1655774) and has filed since 2023-05-12. 2 filings are on record, the latest on 2025-05-06.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
OncoResponse, Inc's Form D of 2025-05-06 names Clifford Stocks, Alice Bexon, Kamal Puri and 7 more as its officers, directors or promoters.
Its new offerings report $19.91M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Clifford Stocks is named as Director and Executive Officer on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Alice Bexon is named as Executive Officer on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Kamal Puri is named as Executive Officer on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Chris Russell is named as Executive Officer on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Roberto De Ponti is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Carol Gallagher is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Steven Gillis is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Wende Hutton is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
Sean McCarthy is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
John McKearn is named as Director on the Form D that OncoResponse, Inc filed with the SEC on 6 May 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-05-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about OncoResponse, Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on OncoResponse, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OncoResponse, Inc covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist OncoResponse, IncYou get an alert in MentionFox the next time this company shows up.
If you're behind OncoResponse, Inc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for OncoResponse, Inc. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Houston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/oncoresponse-inc-form-d-25000001